SCHEMBL7729066

SCHEMBL7729066

CC(C)(C)OC(=O)N[C@@H]1C[C@@H](C(=O)O)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.54
CTSK P43235 2/20 0.44
HSD11B1 P28845 5/20 0.43
CYP2C9 P11712 1/20 0.43
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MMP2 P08253 1/20 0.39
ANPEP P15144 1/20 0.39
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25235410 1.00 BTK (0.54) BTKCTSKHSD11B1CYP2C9CA1
SCHEMBL7728661 1.00 BTK (0.54) BTKCTSKHSD11B1CYP2C9CA1
SCHEMBL15297652 1.00 BTK (0.54) BTKCTSKHSD11B1CYP2C9CA1
SCHEMBL7722234 1.00 BTK (0.54) BTKCTSKHSD11B1CYP2C9CA1
SCHEMBL7736016 1.00 BTK (0.54) BTKCTSKHSD11B1CYP2C9CA1
SCHEMBL28905732 0.90 BTK (0.55) BTKCTSKHSD11B1CYP2C9CA1
SCHEMBL10594861 0.90 BTK (0.41) BTKCTSKMMP2ANPEPHSD17B10
SCHEMBL10594866 0.90 BTK (0.41) BTKCTSKMMP2ANPEPHSD17B10
SCHEMBL21273886 0.90 BTK (0.55) BTKCTSKHSD11B1CYP2C9CA1
SCHEMBL26097572 0.90 BTK (0.55) BTKCTSKHSD11B1CYP2C9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4405353-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2024-07-31 EP disclosed
US-20230203043-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-06-29 US disclosed
WO-2023041757-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2023-03-23 WO disclosed
EP-2831075-B1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2017-11-08 EP disclosed
WO-2013149121-A1 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS CUBIST PHARMACEUTICALS, INC. (US) 2013-10-03 WO disclosed
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 US disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203043-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES IKZF3, INTS9, CYP2C9 BTK 194/4885CTSK 1925/4885HSD11B1 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.